Ambros Therapeutics

Ambros Therapeutics is a private, clinical-stage biotech developing neridronate for Complex Regional Pain Syndrome Type 1 (CRPS-1), a rare disease with no FDA-approved therapies. The company's lead candidate has received Breakthrough Therapy, Fast Track, and Orphan Drug designations from the FDA, underscoring the significant unmet need and potential of the program. Ambros is currently conducting a single, pivotal Phase 3 trial (CRPS-RISE) in the U.S., positioning it as a potential first-in-class therapy. The company operates with a focused pipeline and is based in Irvine, California.

Development and repurposing of neridronate, a differentiated third-generation bisphosphonate, for novel indications.

CRPS-1 has no approved pharmacologic therapies, creating an open competitive landscape. Neridronate's primary competition consists of off-label use of various drug classes (e.g., other bisphosphonates, NSAIDs, anticonvulsants, opioids) and non-pharmacologic interventions, none of which are approved or consistently effective for the condition.